Polymorphism of the β3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine

Rheumatology International

Volumn 23, Issue 3, 2003, Pages 99-103

  Munoz Valle J F ^a   Vazquez Del Mercado M ^a,b   Ruiz Quezada, S ^a   Oregon Romero E ^a   Navarro Hernandez R E ^a   Ramirez Barragan J ^a   Martinez Bonilla G ^a,b   Bernard Medina, G ^b   Bastidas Ramirez B E ^a   Ruiz Madrigal, B ^a   Panduro, A ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Beta 3 adrenergic receptor; Chloroquine; Dyslipidemia; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; CHLOROQUINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; DRUG EFFECT; EXON; FEMALE; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038173812     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-002-0266-z     Document Type: Article

References (44)

1. De Blasi A (1990) Beta-adrenergic receptors: structure, function and regulation. Drugs Exp Clin Res 16:107-112
2. Emorine LJ, Marullo S, Brien-Sutrend MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989) Molecular characterization of human β3-adrenergic receptor. Science 245:1118-1121
3. Strader CD, Sigal IS, Dixon RAF (1989) Structural basis of β-adrenergic receptor function. FASEB J 3:1825-1832
4. 3-adrenergic receptor. Ann Rev Pharmacol Toxicol 37:421-450
5. García-Rubi E, Calles EJ (1999) Insulin resistance and type 2 diabetes mellitus: its relationship with the β3-adrenergic receptor. Arch Med Res 30:459-464
6. 3-adrenergic receptor mRNA in man. J Clin Invest 91:344-349
7. 3-adrenergic receptors in obesity. J Clin Invest 95:1109-1116
8. 3-adrenergic receptor gene. N Engl J Med 333:343-347
9. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352-354
10. 3-adrenergic receptor gene and response to treatment of obesity. Lancet 346:1433-1434
11. 3-adrenergic receptor polymorphism: a genetic marker for visceral fat obesity and the insulin resistance syndrome. Diabetologia 40:200-204
12. 3-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Diabetes 45:1358-1363
13. 3-adrenergic receptor gene on body fat, plasma glucose level, lipid profile, insulin secretion and action in Chinese. Chung Hua I Chuan Hsueh Tsa Chih 15:337-340
14. 3-adrenoreceptor gene polymorphism: a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes 46:1633-1636
15. Isomaki HA, Mutru O, Koota K (1975) Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 4:205-208
16. Mutru O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and cause of death in patients with RA. BMJ 290:1797-1799
17. Pincus T, Callahan LF (1986) Taking mortality in RA seriously - predictive markers, socioeconomic status and co-morbidity. J Rheumatol 13:841-845
18. Pinals RS (1987) Survival in rheumatoid arthritis. Arthritis Rheum 30:473-475
19. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH, Lee J (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701-1704
20. Ettinger WH, Goldberg AP, Applebaum-Bowden D (1987) Dyslipoproteinemia in systemic lupus erythematosus. Am J Med 83:503-508
21. Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859-863
22. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest JR (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26:2363-2368
23. Bruce IN, Urowitz MB, Gladman DD, Hallett DC (1999) Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26:2137-2143
24. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern P (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89:322-326
25. Hodis HN, Quismorio FP, Wickham JR, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661-665
26. Wallace DJ (1994) Antimalarial agents and lupus. In: Systemic lupus erythematosus. Rheum Dis Clin North Am 20:243-263
27. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J (1997) Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 3:3-8
28. Gladman DD, Urowitz MB, Senecal JL, Fortin PJR, Petty RE, Esdaile JM, Carrette S, Edworthy SM, Smith CD, Thorne JC (1998) Workshop report. Aspects of use of antimalarials in systemic lupus erythematosus. J Rheumatol 25:983-985
29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
31. Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19:1551-1558
32. Van Gestel AM, Haagsma CJ, Van Riel PLCM (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845-1850
33. Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215-1219
34. Manzi S, Meilahn EN, Rairie JE (1997) Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 145:408-415
35. Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for CAD in patients with systemic lupus erythematosus. Am J Med 93:513-519
36. Gladman DD, Urowitz MB (1987) Morbidity in systemic lupus erythematosus. J Rheumatol 14 [Suppl 13]:223-226
37. De Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23:2495-2531
38. Nossen JO, Rustan AC, Barnard T, Drevon CA (1984) Inhibition by chloroquine of the secretion of very low density lipoproteins by cultured rat hepatocytes. Biochem Biophys Acta 803:11-20
39. Rustan AC, Nossen JO, Tefre T, Drevon CA (1987) Inhibition of very low density lipoprotein secretion by chloroquine, verapamil, and monensin takes place in the Golgi complex. Biochem Biophys Acta 930:311-319
40. Chen HW, Leonard DA (1984) Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J Biol Chem 259:8156-8162
41. Beynen AC, Van Der Molen AJ, Geelen MJH (1981) Inhibition of hepatic cholesterol by biosynthesis by chloroquine. Lipids 16:472-474
42. Goldstein JL, Brunschede GY, Brown MS (1975) Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A and Triton WR 1339. J Biol Chem 250:7854-7862
43. Goldstein JL, Brown MS (1976) The LDL pathway in human fibroblast: a receptor mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul 11:147-181
44. Svenson KLG, Lithell H, Hallgren R, Vessby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease modifying drug treatment. Arch Intern Med 147:1917-1920